2 min read
At the 2016 Duke Industry Statistics Symposium, Dr. Robin Bliss, in collaboration with Dr. Jing Wang of Gilead Sciences, lead a discussion on “Biomarker-Driven Clinical Trial Designs for Precision Medicine.” Dr. Bliss highlighted two Adaptive Enrichment...
2 min read
Today we announced that we have been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.
4 min read
An adaptive design is a clinical trial design that allows adaptations or modifications to aspects of the trial after its initiation without undermining the validity and integrity of the trial. An adaptive design consists of multiple stages. At each...
2 min read
If you're reading this as a biostatistician or clinical trial professional, you know that the pharmaceutical industry is shifting from classical to adaptive clinical trial design in an effort to reduce NDA failure rate, lower the cost of research and...
1 min read
Veristat joined over 6500+ life sciences professionals at the Drug Information Associations (DIA) Annual Meeting that recently took place in Philadelphia, PA. The conference featured over 175 topics in 25 tracks covering the latest innovations, trends,...
1 min read
Veristat announced today that it is continuing its accelerated growth and geographic expansion with the opening of an office in Raleigh-Durham, North Carolina. In addition to this newly planned North Carolina office, Veristat has additional North...
2 min read
1 min read
The Role of Transparency in CRO-Sponsor Partnerships: Enabling Better Collaboration Models
1 min read
Join Veristat, as well as Chief Medical Officers and R&D Executives from small to mid-sized life science companies at the Chief Medical Officer Summit East 2016 to share ideas, solutions and support for bringing new products through the clinical...